Telehealth exercise to Improve Physical function and frailty in patients with multiple myeloma treated with autologous hematopoietic Stem cell transplantation (TIPS): protocol of a randomized controlled trial.

Autor: Lee K; Division of Outcomes Research, Department of Population Sciences, Beckman Research Institute, City of Hope Comprehensive Cancer Center, 1500 E. Duarte Rd., Bldg. 173, Duarte, CA, 91010, USA. kylee@coh.org., Nathwani N; Division of Multiple Myeloma, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, Duarte, CA, 91010, USA., Shamunee J; Division of Outcomes Research, Department of Population Sciences, Beckman Research Institute, City of Hope Comprehensive Cancer Center, 1500 E. Duarte Rd., Bldg. 173, Duarte, CA, 91010, USA., Lindenfeld L; Division of Outcomes Research, Department of Population Sciences, Beckman Research Institute, City of Hope Comprehensive Cancer Center, 1500 E. Duarte Rd., Bldg. 173, Duarte, CA, 91010, USA., Wong FL; Division of Outcomes Research, Department of Population Sciences, Beckman Research Institute, City of Hope Comprehensive Cancer Center, 1500 E. Duarte Rd., Bldg. 173, Duarte, CA, 91010, USA., Krishnan A; Division of Multiple Myeloma, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, Duarte, CA, 91010, USA., Armenian S; Division of Outcomes Research, Department of Population Sciences, Beckman Research Institute, City of Hope Comprehensive Cancer Center, 1500 E. Duarte Rd., Bldg. 173, Duarte, CA, 91010, USA.
Jazyk: angličtina
Zdroj: Trials [Trials] 2022 Nov 03; Vol. 23 (1), pp. 921. Date of Electronic Publication: 2022 Nov 03.
DOI: 10.1186/s13063-022-06848-y
Abstrakt: Background: Advances in autologous hematopoietic stem cell transplantation (HSCT) and supportive care have led to marked improvements in survival for patients with multiple myeloma. Despite these improvements, patients with multiple myeloma remain at high risk of physical dysfunction and frailty due to HSCT and its associated exposures. Although traditional supervised exercise programs can improve frailty in cancer patients and survivors, rehabilitation facilities are typically far from a patient's residence, are offered on fixed days/hours, contain uniform activities for everyone, and carry a higher risk of contact cross-infection due to immunosuppression, which can be barriers to exercise participation. Innovative personalized interventions are needed to overcome the limitations of traditional exercise interventions. The purpose of this study is to determine the efficacy and sustainability of a telehealth exercise intervention on physical function and frailty in patients with multiple myeloma treated with HSCT.
Methods: This randomized controlled trial will assess the efficacy of an 8-week telehealth exercise intervention in 60 patients with multiple myeloma who underwent autologous HSCT (30-180 days post-transplant) and are pre-frail or frail. There will be 30 intervention participants and 30 delayed controls. We will administer remote baseline assessments (week 0), followed by an 8-week telehealth intervention (week 1-8), post assessment (week 9), and an additional follow-up assessment (week 17). Our primary endpoint will be improved physical function, as assessed by the Short Physical Performance Battery test. Our secondary endpoint will be a decrease in frailty characteristics such as gait speed, strength, and fatigue. We will also evaluate the sustainability of improved physical function and frailty at week 17. Participants randomized to the intervention group will perform at least 90 min of exercise per week throughout the 8 weeks.
Discussion: This study will help optimize the delivery of safe, low-cost, and scalable telehealth exercise interventions to improve health outcomes in patients with multiple myeloma, an understudied population at high risk for physical dysfunction and frailty. Our study may provide the foundation for sustainable telehealth exercise interventions to improve physical function and frailty for other hematologic cancer patients (e.g., acute leukemia, lymphoma) as well as any other cancer population of interest.
Trial Registration: ClinicalTrials.gov NCT05142371 . This study was retrospectively registered on December 2nd, 2021, and is currently open to accrual.
(© 2022. The Author(s).)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje